Table 2. Incidence Density Rates of Hematuria-Related Complications for Each Antithrombotic Agent Exposure (Study Interval Between 2002-2014).
| Variable | Sample Size | Exposure Time (Person-Years) | Any Hematuria-Related Complication | Emergency Department Visits | Hospitalizations | Urologic Procedures | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Events | Incidence Density Ratea | No. of Events | Incidence Density Ratea | No. of Events | Incidence Density Ratea | No. of Events | Incidence Density Ratea | |||
| No antithrombotic | 1 709 167 | 15 864 708 | 1 271 901 | 80.17 | 39 846 | 2.51 | 85 941 | 5.42 | 1 146 077 | 72.24 |
| Any antithromboticb | 808 897 | 2 600 520 | 322 322 | 123.95 | 18 322 | 7.05 | 28 905 | 11.12 | 275 076 | 105.78 |
| Difference from no antithrombotic (95% CI) | 43.8 (43.0-44.6) |
4.5 (4.3-4.7) |
5.7 (5.5-5.9) |
33.5 (32.8-34.3) |
||||||
| Aspirin | 315 639 | 795 686 | 75 033 | 94.3 | 3180 | 4.00 | 5353 | 6.73 | 66 498 | 83.57 |
| Difference from no aspirin (95% CI)c | 8.3 (7.7-9.0) |
0.9 (0.7-1.0) |
0.5 (0.3-0.7) |
8.9 (8.3-9.5) |
||||||
| Other antiplatelet | 275 887 | 706 988 | 91 927 | 130.03 | 4621 | 6.54 | 7823 | 11.07 | 79 477 | 112.42 |
| Difference from no other antiplatelet (95% CI)c | 45.4 (44.6-4.2) |
3.5 (3.3-3.7) |
5.0 (4.8-5.3) |
36.8 (36.1-37.6) |
||||||
| Apixiban | 15 102 | 6612 | 1085 | 164.09 | 76 | 11.50 | 132 | 19.96 | 877 | 132.64 |
| Difference from no apixiban (95% CI)c | 77.8 (68.9-86.7) |
8.3 (5.8-10.9) |
13.7 (10.4-17.1) |
55.7 (47.5-63.9) |
||||||
| Dabigatran | 43 451 | 57 675 | 8319 | 144.24 | 626 | 10.85 | 932 | 16.16 | 6760 | 117.21 |
| Difference from no dabigatran (95% CI)c | 58.1 (55.2-61.0) |
7.7 (6.9-8.6) |
10.0 (8.9-11.0) |
40.4 (37.7-43.0) |
||||||
| Rivaroxaban | 87 912 | 40 668 | 7672 | 188.65 | 766 | 18.84 | 922 | 22.67 | 5984 | 147.14 |
| Difference from no rivaroxaban (95% CI)c | 102.5 (98.7-106.3) |
15.7 (14.4-17.0) |
16.5 (15.0-17.9) |
70.3 (66.9-73.8) |
||||||
| Warfarin | 320 347 | 887 691 | 123 100 | 138.67 | 8804 | 9.92 | 12 468 | 14.05 | 101 816 | 114.70 |
| Difference from no warfarin (95% CI)c | 55.0 (54.2-55.7) |
7.1 (6.9-7.3) |
8.2 (7.9-8.4) |
39.6 (39.0-40.3) |
||||||
a
Incidence density rates are expressed as the number of events per 1000 person-years.
b
Totals in the “any antithrombotic” category may not equal the total of the component exposures owing to concurrent exposure.
c
Each drug has different nonexposure time; difference in incidence density rate for each drug is not based on “No antithrombotic” row.